Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKAN Akanda	$1.26 -3.8%	$1.29	$0.93 ▼ $2.82	$1.80M	1.59	559,038 shs	4.28 million shs
APM Aptorum Group	$2.64 -37.9%	$1.36	$0.46 ▼ $7.49	$14.12M	-0.1	19.99 million shs	13.26 million shs
KPRX Kiora Pharmaceuticals	$2.73 +4.2%	$2.85	$2.25 ▼ $4.18	$9.37M	-0.64	87,042 shs	27,058 shs
MTNB Matinas Biopharma	$2.13 +22.4%	$1.10	$0.47 ▼ $5.24	$10.84M	1.32	448,793 shs	358,565 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKAN Akanda	-3.82%	-7.35%	-2.33%	0.00%	-55.94%
APM Aptorum Group	-37.88%	+89.93%	+36.79%	+197.33%	-14.84%
KPRX Kiora Pharmaceuticals	+4.20%	-6.83%	-12.22%	-10.78%	-33.41%
MTNB Matinas Biopharma	+22.41%	-9.75%	+123.27%	+162.32%	+1,047.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKAN Akanda	1.1318 of 5 stars	0.0	3.0	3.0	1.7	0.6
APM Aptorum Group	0.7324 of 5 stars	0.0	2.0	3.9	1.7	0.0
KPRX Kiora Pharmaceuticals	2.7639 of 5 stars	3.3	5.0	1.1	1.7	0.6
MTNB Matinas Biopharma	0.6973 of 5 stars	0.0	5.0	1.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKAN Akanda	0.00	N/A	N/A	N/A
APM Aptorum Group	0.00	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	2.50	Moderate Buy	$10.00	266.30% Upside
MTNB Matinas Biopharma	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest AKAN, KPRX, MTNB, and APM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/13/2025	KPRX Kiora Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKAN Akanda	$840K	2.15	N/A	N/A	$3.00 per share	0.42
APM Aptorum Group	$430K	32.85	N/A	N/A	$2.20 per share	1.20
KPRX Kiora Pharmaceuticals	$16.02M	0.58	$1.24 per share	2.20	$6.44 per share	0.42
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	$4.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKAN Akanda	-$4.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	$3.60M	-$2.91	N/A	N/A	N/A	N/A	-47.17%	-34.00%	N/A
MTNB Matinas Biopharma	-$22.94M	-$3.89	N/A	∞	N/A	N/A	-123.06%	-94.28%	N/A

Latest AKAN, KPRX, MTNB, and APM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/8/2025	Q2 2025	KPRX Kiora Pharmaceuticals	-$0.58	-$0.54	+$0.04	-$0.54	$0.75 million	$0.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKAN Akanda	N/A	N/A	N/A	N/A	N/A
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKAN Akanda	N/A	1.39	1.39
APM Aptorum Group	N/A	0.22	0.22
KPRX Kiora Pharmaceuticals	N/A	7.76	7.76
MTNB Matinas Biopharma	N/A	5.53	5.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKAN Akanda	1.00%
APM Aptorum Group	3.80%
KPRX Kiora Pharmaceuticals	76.97%
MTNB Matinas Biopharma	11.77%

Insider Ownership

Company	Insider Ownership
AKAN Akanda	20.39%
APM Aptorum Group	63.99%
KPRX Kiora Pharmaceuticals	0.05%
MTNB Matinas Biopharma	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKAN Akanda	110	1.43 million	1.14 million	Not Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
KPRX Kiora Pharmaceuticals	10	3.43 million	3.43 million	Not Optionable
MTNB Matinas Biopharma	30	5.09 million	4.60 million	N/A

AKAN, KPRX, MTNB, and APM Headlines

Recent News About These Companies

MTNB Matinas BioPharma Holdings, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Matinas BioPharma Holdings, Inc. (MTNB) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Kalkine Matinas BioPharma Surges Amid NYSE Composite Market Momentum

June 7, 2025 | kalkinemedia.comK

Matinas BioPharma amends bylaws, updates on officer agreements

May 4, 2025 | investing.com

Matinas BioPharma files to sell 16.9M shares of common stock for holders

April 24, 2025 | markets.businessinsider.com

Matinas BioPharma secures shareholder nods on key proposals

April 6, 2025 | investing.com

Matinas BioPharma announces board chairman’s departure

March 16, 2025 | investing.com

Matinas BioPharma appoints Murphy, Neugeboren to board of directors

March 11, 2025 | markets.businessinsider.com

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

March 11, 2025 | finance.yahoo.com

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

February 13, 2025 | globenewswire.com

Matinas BioPharma announces board member retirement

February 11, 2025 | msn.com

Matinas BioPharma Appoints Evelyn D’An as Independent Director and Audit Committee Chair

February 9, 2025 | nasdaq.com

Matinas BioPharma appoints Evelyn D’An to board of directors

February 7, 2025 | markets.businessinsider.com

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

February 7, 2025 | finance.yahoo.com

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

February 7, 2025 | globenewswire.com

Matinas BioPharma announces board member resignation

January 25, 2025 | msn.com

111 Equity Group increases stake in Matinas BioPharma

January 24, 2025 | markets.businessinsider.com

111 Equity ups stake in Matinas Biopharma Holdings

January 24, 2025 | msn.com

111 Equity Group increases stake in Matinas Biopharma Holdings, Inc.

January 24, 2025 | finance.yahoo.com

What Factors Have Led to Matinas BioPharma Holdings Inc (MTNB) Stock Trading -96.74% Below Its 52-Week High?

January 15, 2025 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKAN, KPRX, MTNB, and APM Company Descriptions

Akanda NASDAQ:AKAN

$1.26 -0.05 (-3.82%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.04 -0.22 (-17.54%)

As of 08/22/2025 07:59 PM Eastern

Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.

Aptorum Group NASDAQ:APM

$2.64 -1.61 (-37.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.54 -0.10 (-3.64%)

As of 08/22/2025 08:00 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.73 +0.11 (+4.20%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.68 -0.05 (-1.83%)

As of 08/22/2025 07:47 PM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Matinas Biopharma NYSE:MTNB

$2.13 +0.39 (+22.41%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.10 -0.03 (-1.36%)

As of 08/22/2025 07:55 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time